Melisa L Wong1, Timothy L McMurry2, George J Stukenborg3, Amanda B Francescatti4, Carla Amato-Martz5, Jessica R Schumacher6, George J Chang7, Caprice C Greenberg8, David P Winchester9, Daniel P McKellar10, Louise C Walter11, Benjamin D Kozower12. 1. Divisions of Hematology/Oncology and Geriatrics, Department of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 505 Parnassus Ave., Mailbox 1270, San Francisco, CA 94143, USA. Electronic address: melisa.wong@ucsf.edu. 2. Department of Public Health Sciences, University of Virginia Health System, PO Box 800717, Charlottesville, VA 22908-0717, USA. Electronic address: tlm6w@eservices.virginia.edu. 3. Department of Public Health Sciences, University of Virginia Health System, PO Box 800717, Charlottesville, VA 22908-0717, USA. Electronic address: gjs6r@eservices.virginia.edu. 4. American College of Surgeons, 633 N. Saint Clair Street, Chicago, IL 60611, USA. Electronic address: afrancescatti@facs.org. 5. Alliance for Clinical Trials in Oncology, 125 S. Wacker Drive, Suite 1600, Chicago, IL 60606, USA. Electronic address: cmartz@alliancefoundationtrials.org. 6. Department of Surgery, University of Wisconsin, 600 Highland Ave., BX7375 Clinical Science Center, Madison, WI 53792-3284, USA. Electronic address: schumacher@surgery.wisc.edu. 7. Departments of Surgical Oncology and Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 444, Houston, TX 77030, USA. Electronic address: GChang@mdanderson.org. 8. Department of Surgery, University of Wisconsin, 600 Highland Ave., BX7375 Clinical Science Center, Madison, WI 53792-3284, USA. Electronic address: greenberg@surgery.wisc.edu. 9. Cancer Programs, American College of Surgeons, 633 N. Saint Clair Street, Chicago, IL 60611, USA. Electronic address: DWinchester@facs.org. 10. Commission on Cancer, American College of Surgeons, 633 N. Saint Clair Street, Chicago, IL 60611, USA. Electronic address: d.mckellar1958@gmail.com. 11. Division of Geriatrics, Department of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement (181G), San Francisco, CA 94121, USA. Electronic address: Louise.Walter@ucsf.edu. 12. Division of Cardiothoracic Surgery, Department of Surgery, Washington University, One Barnes-Jewish Hospital Plaza, Suite 3108, Queeny Tower, St. Louis, MO 63110-1013, USA. Electronic address: kozowerb@wudosis.wustl.edu.
Abstract
OBJECTIVE: Older patients with non-small cell lung cancer (NSCLC) are less likely to receive guideline-recommended treatment at diagnosis, independent of comorbidity. However, national data on treatment of postoperative recurrence are limited. We evaluated the associations between age, comorbidity, and other patient factors and treatment of postoperative NSCLC recurrence in a national cohort. MATERIALS AND METHODS: We randomly selected 9001 patients with surgically resected stage I-III NSCLC in 2006-2007 from the National Cancer Data Base. Patients were followed for 5 years or until first NSCLC recurrence, new primary cancer, or death, whichever came first. Perioperative comorbidities, first recurrence, treatment of recurrence, and survival were abstracted from medical records and merged with existing registry data. Factors associated with active treatment (chemotherapy, radiation, and/or surgery) versus supportive care only were analyzed using multivariable logistic regression. RESULTS: Median age at initial diagnosis was 67; 69.7% had >1 comorbidity. At 5-year follow-up, 12.3% developed locoregional and 21.5% developed distant recurrence. Among patients with locoregional recurrence, 79.5% received active treatment. Older patients (OR 0.49 for age >75 compared with <55; 95% CI 0.27-0.88) and those with substance abuse (OR 0.43; 95% CI 0.23-0.81) were less likely to receive active treatment. Women (OR 0.62; 95% CI 0.43-0.89) and patients with symptomatic recurrence (OR 0.69; 95% CI 0.47-0.99) were also less likely to receive active treatment. Among those with distant recurrence, 77.3% received active treatment. Older patients (OR 0.42 for age >75 compared with <55; 95% CI 0.26-0.68) and those with any documented comorbidities (OR 0.59; 95% CI 0.38-0.89) were less likely to receive active treatment. CONCLUSION: Older patients independent of comorbidity, patients with substance abuse, and women were less likely to receive active treatment for postoperative NSCLC recurrence. Studies to further characterize these disparities in treatment of NSCLC recurrence are needed to identify barriers to treatment.
OBJECTIVE: Older patients with non-small cell lung cancer (NSCLC) are less likely to receive guideline-recommended treatment at diagnosis, independent of comorbidity. However, national data on treatment of postoperative recurrence are limited. We evaluated the associations between age, comorbidity, and other patient factors and treatment of postoperative NSCLC recurrence in a national cohort. MATERIALS AND METHODS: We randomly selected 9001 patients with surgically resected stage I-III NSCLC in 2006-2007 from the National Cancer Data Base. Patients were followed for 5 years or until first NSCLC recurrence, new primary cancer, or death, whichever came first. Perioperative comorbidities, first recurrence, treatment of recurrence, and survival were abstracted from medical records and merged with existing registry data. Factors associated with active treatment (chemotherapy, radiation, and/or surgery) versus supportive care only were analyzed using multivariable logistic regression. RESULTS: Median age at initial diagnosis was 67; 69.7% had >1 comorbidity. At 5-year follow-up, 12.3% developed locoregional and 21.5% developed distant recurrence. Among patients with locoregional recurrence, 79.5% received active treatment. Older patients (OR 0.49 for age >75 compared with <55; 95% CI 0.27-0.88) and those with substance abuse (OR 0.43; 95% CI 0.23-0.81) were less likely to receive active treatment. Women (OR 0.62; 95% CI 0.43-0.89) and patients with symptomatic recurrence (OR 0.69; 95% CI 0.47-0.99) were also less likely to receive active treatment. Among those with distant recurrence, 77.3% received active treatment. Older patients (OR 0.42 for age >75 compared with <55; 95% CI 0.26-0.68) and those with any documented comorbidities (OR 0.59; 95% CI 0.38-0.89) were less likely to receive active treatment. CONCLUSION: Older patients independent of comorbidity, patients with substance abuse, and women were less likely to receive active treatment for postoperative NSCLC recurrence. Studies to further characterize these disparities in treatment of NSCLC recurrence are needed to identify barriers to treatment.
Authors: Dario Consonni; Mariaelena Pierobon; Mitchell H Gail; Maurizia Rubagotti; Melissa Rotunno; Alisa Goldstein; Lynn Goldin; Jay Lubin; Sholom Wacholder; Neil E Caporaso; Pier Alberto Bertazzi; Margaret A Tucker; Angela C Pesatori; Maria Teresa Landi Journal: J Natl Cancer Inst Date: 2015-03-23 Impact factor: 13.506
Authors: Arti Hurria; Laura A Levit; William Dale; Supriya G Mohile; Hyman B Muss; Louis Fehrenbacher; Allison Magnuson; Stuart M Lichtman; Suanna S Bruinooge; Enrique Soto-Perez-de-Celis; William P Tew; Michael A Postow; Harvey J Cohen Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Robert A Hiatt; Caroline G Tai; Douglas W Blayney; Dennis Deapen; Michael Hogarth; Kenneth W Kizer; Joseph Lipscomb; Jennifer Malin; Stephen K Phillips; John Santa; Deborah Schrag Journal: J Natl Cancer Inst Date: 2015-03-11 Impact factor: 13.506
Authors: James Huang; Amy E Logue; Jamie S Ostroff; Bernard J Park; Mary McCabe; David R Jones; Manjit S Bains; Nabil P Rizk; Mark G Kris; Valerie W Rusch Journal: Ann Thorac Surg Date: 2014-07-31 Impact factor: 4.330
Authors: M Saunders; J P Sculier; D Ball; M Capello; K Furuse; P Goldstraw; A P Meert; V Ninane; Y Ohe; M Paesmans; K Park; R Pirker; P Postmus; Y Sokolow Journal: Lung Cancer Date: 2003-12 Impact factor: 5.705
Authors: Melisa L Wong; Stuart M Lichtman; Gary R Morrow; John Simmons; Tomma Hargraves; Cary P Gross; Jennifer L Lund; Lisa M Lowenstein; Louise C Walter; Cara L McDermott; Supriya G Mohile; Harvey Jay Cohen Journal: J Geriatr Oncol Date: 2019-07-17 Impact factor: 3.599
Authors: Lauren L Palazzo; Deirdre F Sheehan; Angela C Tramontano; Chung Yin Kong Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-20 Impact factor: 4.254
Authors: Melisa L Wong; Timothy L McMurry; Jessica R Schumacher; Chung-Yuan Hu; George J Stukenborg; Amanda B Francescatti; Caprice C Greenberg; George J Chang; Daniel P McKellar; Louise C Walter; Benjamin D Kozower Journal: J Oncol Pract Date: 2018-09-12 Impact factor: 3.840
Authors: Timothy L McMurry; George J Stukenborg; Larry G Kessler; Graham A Colditz; Melisa L Wong; Amanda B Francescatti; David R Jones; Jessica R Schumacher; Caprice C Greenberg; George J Chang; David P Winchester; Daniel P McKellar; Benjamin D Kozower Journal: Ann Surg Date: 2018-10 Impact factor: 12.969